Paul Stephen Aisen
professor
medicine
Keck School of Medicine
United Kingdom
Biography
Paul Aisen, M.D., has been appointed founding director of USC ATRI. Aisen has been a leading figure in Alzheimer’s disease research for more than two decades, having developed novel methodologies as well as designed and directed many large therapeutic trials. He received his B.A. in biochemistry and molecular biology from Harvard and his medical degree from Columbia. He completed his residency at Case Western Reserve University in Cleveland and Mount Sinai Medical Center in New York, and then fellowship training in rheumatology at New York University. After serving as chief medical resident at Mount Sinai, he began a solo practice in internal medicine and rheumatology in New York. Aisen joined the faculty of Mount Sinai in 1994 and was recruited to Georgetown University in 1999 as a professor of neurology and medicine. That year, he founded the Memory Disorders Program, a clinical and research program for Alzheimer’s disease and related disorders. He continued basic research studies on therapeutic targets and biomarkers and designed and directed multicenter therapeutic trials. He became vice chair of the Department of Neurology at Georgetown in 2004. From 2007 through 2015, he was professor in the Department of Neurosciences at the University of California, San Diego and director of the Alzheimer’s Disease Cooperative Study.
Research Interest
Sports medicine (anabolic steroid use, performance enhancers, adolescent health) Medicine and the law Drug-drug interactions Delay in diagnosis Pediatric and adolescent sports medicine Advanced MRI techniques for OA AND MENISCAL TEAR Sports medicine (anabolic steroid use, performance enhancers, adolescent health) Medicine and the law Drug-drug interactions Delay in diagnosis
Publications
-
Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2017 Aug 18; 60:92-103. View in: PubMed
-
The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults. J Alzheimers Dis. 2017 Aug 21. View in: PubMed
-
Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid ß. Alzheimers Dement. 2017 Sep; 13(9):1004-1012. View in: PubMed